Protagonist Therapeutics annual operating margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
Protagonist Therapeutics Operating Margin Growth & History (PTGX)
Protagonist Therapeutics's operating margin was −343.63% for fiscal 2025.
View full Protagonist Therapeutics company overviewProtagonist Therapeutics annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −343.63% | −401.84 pp |
| 2024 | 2024-12-31 | 58.20% | +214.29 pp |
| 2023 | 2023-12-31 | −156.09% | +338.15 pp |
| 2022 | 2022-12-31 | −494.24% | −34.23 pp |
| 2021 | 2021-12-31 | −460.01% | −234.65 pp |
| 2020 | 2020-12-31 | −225.36% | +34632.22 pp |
| 2019 | 2019-12-31 | −34,857.58% | −34720.89 pp |
| 2018 | 2018-12-31 | −136.68% | +52.21 pp |
| 2017 | 2017-12-31 | −188.89% | — |
Protagonist Therapeutics quarterly operating margin
Q3.17
Q1.18
Q3.18
Q1.19
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 74.37% | +832.41 pp |
| Q1 2026 | 2026-03-31 | −6.47% | +61.71 pp |
| Q4 2025 | 2025-12-31 | −677.09% | −751.39 pp |
| Q3 2025 | 2025-09-30 | −985.17% | −98.47 pp |
| Q2 2025 | 2025-06-30 | −758.04% | +172.92 pp |
| Q1 2025 | 2025-03-31 | −68.18% | −149.10 pp |
| Q4 2024 | 2024-12-31 | 74.30% | +35.88 pp |
| Q3 2024 | 2024-09-30 | −886.70% | +3937.87 pp |
| Q2 2024 | 2024-06-30 | −930.96% | −848.88 pp |
| Q1 2024 | 2024-03-31 | 80.92% | +510.49 pp |
| Q4 2023 | 2023-12-31 | 38.42% | +368.24 pp |
| Q2 2022 | 2022-06-30 | −4,824.56% | −3461.12 pp |
| Q1 2022 | 2022-03-31 | −82.07% | +306.05 pp |
| Q4 2021 | 2021-12-31 | −429.57% | −370.30 pp |
| Q3 2021 | 2021-09-30 | −329.83% | +609.15 pp |
| Q2 2021 | 2021-06-30 | −1,363.44% | −1209.95 pp |
| Q1 2021 | 2021-03-31 | −388.12% | −311.80 pp |
| Q3 2020 | 2020-09-30 | −59.26% | −2.55 pp |
| Q1 2019 | 2019-03-31 | −938.97% | — |
| Q3 2018 | 2018-09-30 | −153.49% | — |
| Q1 2018 | 2018-03-31 | −76.33% | — |
| Q3 2017 | 2017-09-30 | −56.71% | — |
Protagonist Therapeutics operating margin trends
Over the last five reported fiscal years, Protagonist Therapeutics's operating margin decreased from −225.36% to −343.63%, a change of −118.28 percentage points. The latest reported quarter, Q2 2026, shows 74.37%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagonist Therapeutics filings at SEC.gov ↗